The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
about
PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesInflammatory etiopathogenesis of systemic lupus erythematosus: an updateAnimal models of anti-neutrophil cytoplasmic antibody-associated vasculitisIntracellular nucleic acid sensors and autoimmunitySmall molecules in the treatment of systemic lupus erythematosusAutophagy in plasma cell pathophysiologyTreatment options and strategies for antibody mediated rejection after renal transplantationNovel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat modelRegulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Emerging Therapies for Rheumatoid ArthritisEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaIdentification of gp96 as a novel target for treatment of autoimmune disease in miceProteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectorsThe pathogenesis, diagnosis and treatment of lupus nephritis.Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice.Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trialGlobal H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome.Mechanisms of Autoantibody-Induced Pathology.Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic targetImmunomodulatory properties of stem cells from human exfoliated deciduous teethHistopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejectionProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsTreatment of chronic graft-versus-host disease with bortezomibBortezomib in kidney transplantation.Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusReactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma ModelMurine models of systemic lupus erythematosusNo evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritisActivation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceProteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome.A review of the mammalian unfolded protein response.
P2860
Q24323912-10F5D825-DD82-4E92-91F0-45E064C089CAQ26751959-673F3E5A-29B6-41F3-9E3E-319C51558C0BQ26796413-63AC1AB7-094E-4EB4-882A-30E32BB65E4EQ26864089-F6045904-2DC5-4461-B5E8-AA4B6EF5ECAFQ26997316-790B50FD-8BA8-46F8-B9DB-87820A39EBF8Q27010090-A9420538-AC20-4774-8384-D0168F5EE6D5Q27015920-468D9293-B858-4539-B14F-8441DB4D8425Q27021397-AEA0F06E-C0B1-4960-A811-4BF84BEEFA87Q27315858-FC523774-1783-4105-A8CE-F447EE36B728Q27686770-A1079EF1-A8AF-460B-8A9D-CE08E2130ADFQ28078943-7CEA30D2-C2DE-4EA6-A1FC-CD01955A5561Q28265144-6E0D8032-ED5B-4E9A-8FF3-DACF88DFAB81Q28473392-C728C3DA-ACFA-4292-B6BB-DDD3E8A70F87Q28730577-002EC1A2-9741-41D4-8721-4CF596B8D20CQ30596968-B91A6713-9321-4C25-A143-FD6C0A12C773Q30894991-505EA0BA-3ED1-4C99-8079-FF9DB6297B62Q31101725-A5265C02-98F5-4F96-9CD4-8091C7142BB9Q33430998-2C64E6E3-D9B5-486E-9F6E-0FD3FC6E692BQ33438199-039BC5EC-3E74-4D55-B5BF-AD2ACECA4DAFQ33584895-AE698298-1036-4C18-83E1-4CBECF34AA8FQ33703372-A6877D22-49FB-413B-A47F-5DFA99B5F157Q33715480-A25367D7-639D-46EA-B888-F34DE08BAFDAQ33740580-2B6B9779-46CA-486B-AEE5-B541E9D2FC2EQ33842215-680B6DD4-DDA9-4168-BEDF-DDBBF32AEA1CQ33865256-0B7D84A9-B604-40CE-8856-562B12C6DD21Q34018912-2703CD93-FD7C-40DC-B422-180070A3B5AEQ34085747-84E338FD-E139-46D6-89CF-31A9CD8D8BA2Q34137032-678F96F8-6DA9-4F16-BD41-B870351F2B05Q34189435-B5A1069B-F83A-4770-A923-C9776AA01F9AQ34222685-C3C343F7-0EA3-4A66-BBAA-2985C4581B91Q34267100-ACD333BA-FE56-4630-8A5F-D4AADBF22713Q34464260-EC91360A-8511-498F-9BA3-D6D6EBB43F6CQ34471099-85D863BF-DC7A-4F64-86EE-1E89DCF44698Q34478543-EA3A8C67-3E1A-4313-A541-CEF3A70BA775Q34591019-16C19FE8-E55F-4A10-A78D-19172CBB7FEFQ34764677-385A75F4-96B5-4848-9995-467357B83671Q34773996-F0A018B1-B88A-4664-83F3-2248C9D59060Q35070412-93D36D37-0B43-4A84-8A10-5A04B9525F56Q35202606-ED180100-3599-40C4-8461-145974301D19Q35354864-FFD08AF6-FCF5-4D46-85FA-F1D24AF17972
P2860
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The proteasome inhibitor borte ...... s-like disease from nephritis.
@en
The proteasome inhibitor borte ...... s-like disease from nephritis.
@nl
type
label
The proteasome inhibitor borte ...... s-like disease from nephritis.
@en
The proteasome inhibitor borte ...... s-like disease from nephritis.
@nl
prefLabel
The proteasome inhibitor borte ...... s-like disease from nephritis.
@en
The proteasome inhibitor borte ...... s-like disease from nephritis.
@nl
P2093
P356
P1433
P1476
The proteasome inhibitor borte ...... s-like disease from nephritis.
@en
P2093
Carsten Wiethe
Damian Maseda
Florian Weisel
Joachim R Kalden
Katrin Moser
Kerstin Amann
Kirsten Neubert
Reinhard E Voll
Rudolf A Manz
Silke Meister
P2888
P304
P356
10.1038/NM1763
P407
P577
2008-06-08T00:00:00Z